These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33676783)

  • 1. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
    Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
    Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
    Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C
    Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
    Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
    Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
    Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
    Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
    Lv H; Wang S; Liang Z; Yu W; Yan C; Chen Y; Hu X; Fu R; Zheng M; Group T; Luxembourg A; Liao X; Chen Z
    Vaccine; 2022 May; 40(23):3263-3271. PubMed ID: 35487814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV).
    Boey L; Curinckx A; Roelants M; Derdelinckx I; Van Wijngaerden E; De Munter P; Vos R; Kuypers D; Van Cleemput J; Vandermeulen C
    Clin Infect Dis; 2021 Aug; 73(3):e661-e671. PubMed ID: 33373429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
    Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine.
    Klein NP; Wiesner A; Bautista O; Group T; Kanu K; Li ZL; McCauley J; Saxena K; Tota J; Luxembourg A; Bonawitz R
    Pediatrics; 2024 Aug; 154(2):. PubMed ID: 38978512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.
    Landier W; Bhatia S; Wong FL; York JM; Flynn JS; Henneberg HM; Singh P; Adams K; Wasilewski-Masker K; Cherven B; Jasty-Rao R; Leonard M; Connelly JA; Armenian SH; Robison LL; Giuliano AR; Hudson MM; Klosky JL
    Lancet Child Adolesc Health; 2022 Jan; 6(1):38-48. PubMed ID: 34767765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the 9-valent HPV vaccine in men.
    Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
    Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men.
    Giuliano AR; Wilkin T; Bautista OM; Cheon K; Connor L; Dubey S; ; Luxembourg A; Rawat S; Shaw A; Velicer C; Vendetti N; Tu Y
    Contemp Clin Trials; 2022 Apr; 115():106592. PubMed ID: 34678491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of a 9-Valent HPV Vaccine.
    Van Damme P; Olsson SE; Block S; Castellsague X; Gray GE; Herrera T; Huang LM; Kim DS; Pitisuttithum P; Chen J; Christiano S; Maansson R; Moeller E; Sun X; Vuocolo S; Luxembourg A
    Pediatrics; 2015 Jul; 136(1):e28-39. PubMed ID: 26101366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals.
    Teppler H; Bautista O; ; Flores S; McCauley J; Luxembourg A
    Contemp Clin Trials; 2021 Jun; 105():106403. PubMed ID: 33857679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.